{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:27:40Z","timestamp":1789504060548,"version":"build-2803163510"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Allergan Aesthetics"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>OnabotulinumtoxinA 20 U reduces glabellar line (GL) severity at maximum frown for approximately 3 to 4 months. Small studies have suggested that &amp;gt;20-U doses may increase the efficacy and duration of response for GLs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim of this study was to evaluate safety, pharmacodynamic response, and treatment satisfaction with onabotulinumtoxinA doses \u226520 U for GLs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This 48-week, double-blind study compared 40, 60, and 80 U onabotulinumtoxinA vs 20 U and placebo in women with moderate or severe dynamic GLs on the Allergan Facial Wrinkle Scale. The following parameters were evaluated: the percentage of subjects with investigator-assessed \u22651-grade Facial Wrinkle Scale improvement from baseline at maximum frown (responders) at Week 24; the estimated median duration of response; the proportion of mostly\/very satisfied responders on the Facial Line Satisfaction Questionnaire follow-up Items 1 to 5; and treatment-emergent adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The modified intent-to-treat population (N\u2005=\u2005226) had a mean age of 48.0 years, with similar baseline GL severity between treatment groups. Week 24 responder rates were 0% for placebo and 16.0%, 32.0%, 30.6%, and 38.5% for onabotulinumtoxinA 20, 40, 60, and 80 U, with significant (P\u2005&amp;lt;\u20050.05) differences for 40 and 80 U vs 20 U. Median duration of response was longer with all higher doses vs 20 U (\u226524.0 vs 19.7 weeks; P\u2005&amp;lt;\u20050.05 vs 20 U at Week 24). Facial Line Satisfaction Questionnaire results indicated high subject satisfaction. The incidence and severity of treatment-emergent adverse events did not exhibit a dose-response effect.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>GL treatment with onabotulinumtoxinA doses &amp;gt;20 U demonstrated longer duration of response and higher patient-reported satisfaction vs the on-label 20-U dose with no apparent impact on safety variables.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Level of Evidence: 2<\/jats:title>\n                  <jats:p\/>\n               <\/jats:sec>","DOI":"10.1093\/asj\/sjac157","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T15:52:26Z","timestamp":1655308346000},"page":"1318-1327","source":"Crossref","is-referenced-by-count":26,"title":["Safety, Pharmacodynamic Response, and Treatment Satisfaction With OnabotulinumtoxinA 40 U, 60 U, and 80 U in Subjects With Moderate to Severe Dynamic Glabellar Lines"],"prefix":"10.1093","volume":"42","author":[{"given":"John H","family":"Joseph","sequence":"first","affiliation":[{"name":"Clinical Testing of Beverly Hills , Beverly Hills, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie D","family":"Palm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee Anna","family":"Glaser","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Saint Louis University School of Medicine , St. Louis, MO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Yoelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue Ellen","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fagien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Sangha","sequence":"additional","affiliation":[{"name":"Research and Development, Allergan Aesthetics, an AbbVie Company , Irvine, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Maltman","sequence":"additional","affiliation":[{"name":"Research and Development, Allergan Aesthetics, an AbbVie Company , Irvine, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Lei","sequence":"additional","affiliation":[{"name":"Research and Development, Allergan Aesthetics, an AbbVie Company , Irvine, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell F","family":"Brin","sequence":"additional","affiliation":[{"name":"Research and Development, Allergan Aesthetics, an AbbVie Company , Irvine, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"2022101312234918700_CIT0001","volume-title":"Botox Cosmetic [package insert]","year":"2020"},{"issue":"6","key":"2022101312234918700_CIT0002","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1067\/mjd.2002.121356","article-title":"A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines","volume":"46","author":"Carruthers","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"5 suppl","key":"2022101312234918700_CIT0003","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1097\/01.PRS.0000076504.79727.62","article-title":"Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin A for patients with glabellar lines","volume":"112","author":"Carruthers","year":"2003","journal-title":"Plast Reconstr Surg"},{"issue":"11","key":"2022101312234918700_CIT0004","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1111\/j.1524-4725.2012.02582.x","article-title":"OnabotulinumtoxinA: a meta-analysis of duration of effect in the treatment of glabellar lines","volume":"38","author":"Glogau","year":"2012","journal-title":"Dermatol Surg"},{"issue":"4","key":"2022101312234918700_CIT0005","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/00042728-200504000-00007","article-title":"Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females","volume":"31","author":"Carruthers","year":"2005","journal-title":"Dermatol Surg"},{"issue":"10","key":"2022101312234918700_CIT0006","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1097\/00042728-200510000-00006","article-title":"Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids","volume":"31","author":"Carruthers","year":"2005","journal-title":"Dermatol Surg"},{"issue":"3","key":"2022101312234918700_CIT0007","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/archotol.1997.01900030103013","article-title":"Patient selection in the treatment of glabellar wrinkles with botulinum toxin type A injection","volume":"123","author":"Pribitkin","year":"1997","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"6","key":"2022101312234918700_CIT0008","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1067\/mjd.2002.124070","article-title":"Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow\u2019s feet","volume":"47","author":"Lowe","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2022101312234918700_CIT0009","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mds.870090106","article-title":"Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections","volume":"9","author":"Borodic","year":"1994","journal-title":"Mov Disord"},{"issue":"11","key":"2022101312234918700_CIT0010","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1001\/archderm.140.11.1351","article-title":"Effect of volume and concentration on the diffusion of botulinum exotoxin A","volume":"140","author":"Hsu","year":"2004","journal-title":"Arch Dermatol"},{"issue":"4","key":"2022101312234918700_CIT0011","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/jocd.12166","article-title":"Development and validation of a novel patient-reported treatment satisfaction measure for hyperfunctional facial lines: Facial Line Satisfaction Questionnaire","volume":"14","author":"Pompilus","year":"2015","journal-title":"J Cosmet Dermatol"},{"issue":"5","key":"2022101312234918700_CIT0012","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/dsu.12463","article-title":"Safety of botulinum toxin A in aesthetic treatments: a systematic review of clinical studies","volume":"40","author":"Cavallini","year":"2014","journal-title":"Dermatol Surg"},{"key":"2022101312234918700_CIT0013","first-page":"124","article-title":"Pharmacodynamics and pharmacokinetics chapter 4.","volume-title":"Seminars in Clinical Psychopharmacology","author":"Banham","year":"","edition":"3rd ed"},{"issue":"1","key":"2022101312234918700_CIT0014","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/PRS.0000000000006327","article-title":"DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)","volume":"145","author":"Carruthers","year":"2020","journal-title":"Plast Reconstr Surg"},{"issue":"12","key":"2022101312234918700_CIT0015","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1111\/j.1524-4725.2009.01235.x","article-title":"Randomized, placebo-controlled study of a new botulinum toxin type A for treatment of glabellar lines: efficacy and safety","volume":"35","author":"Brandt","year":"2009","journal-title":"Dermatol Surg"},{"issue":"4","key":"2022101312234918700_CIT0016","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jaad.2019.06.1313","article-title":"DaxibotulinumtoxinA for injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, Phase 3 studies (SAKURA 1 and SAKURA 2)","volume":"82","author":"Bertucci","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"2022101312234918700_CIT0017","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/DSS.0000000000001206","article-title":"Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a Phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo","volume":"43","author":"Carruthers","year":"2017","journal-title":"Dermatol Surg"},{"key":"2022101312234918700_CIT0018","article-title":"BoNT\/A exhibits a linear correlation between dose, peak efficacy and duration of effect in functional assays [poster]","author":"Nicholson"},{"issue":"12","key":"2022101312234918700_CIT0019","first-page":"1544","article-title":"Does increasing the dose of abobotulinumtoxinA impact the duration of effectiveness for the treatment of moderate to severe glabellar lines?","volume":"15","author":"Joseph","year":"2016","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"2022101312234918700_CIT0020","doi-asserted-by":"crossref","first-page":"NP500","DOI":"10.1093\/asj\/sjaa220","article-title":"A double-blind, randomized clinical trial to determine effects of increasing doses and dose-response relationship of incobotulinumtoxinA in the treatment of glabellar rhytids","volume":"41","author":"Polacco","year":"2021","journal-title":"Aesthet Surg J"},{"key":"2022101312234918700_CIT0021","volume-title":"Botox [package insert]","year":"2021"},{"issue":"3","key":"2022101312234918700_CIT0022","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/DSS.0000000000000626","article-title":"Efficacy and safety of onabotulinumtoxinA treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial","volume":"42","author":"Solish","year":"2016","journal-title":"Dermatol Surg"}],"container-title":["Aesthetic Surgery Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjac157\/45066912\/sjac157.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/42\/11\/1318\/46497049\/sjac157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/42\/11\/1318\/46497049\/sjac157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T13:12:43Z","timestamp":1665666763000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asj\/article\/42\/11\/1318\/6608870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6,15]]},"published-print":{"date-parts":[[2022,10,13]]}},"URL":"https:\/\/doi.org\/10.1093\/asj\/sjac157","relation":{},"ISSN":["1090-820X","1527-330X"],"issn-type":[{"value":"1090-820X","type":"print"},{"value":"1527-330X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,6,15]]}}}